Array
(
)
1
> Pathway Inhibitors>Enzyme Inhibitors>Kinase Inhibitors>JAK2-IN-7

Kinase Inhibitors

JAK2-IN-7 View larger

JAK2-IN-7

AT35900

CAS 2593402-36-7

More details

1000 Items

Molarity Calculation Cart®

HOW TO ORDER

$126.00

$126.00 per mg

Quantity Discount Table - Order More To Get More Price Discount

QuantitymgUnit Price ($/mg or $/Unit)Final Price
15 $107.10 Total: $535.50
110 $90.72 Total: $907.20
125 $76.86 Total: $1,921.50
150 $65.52 Total: $3,276.00
1100 $56.70 Total: $5,670.00

Data sheet

Molecular FormulaC26H33N7O
Molecular Weight459.59
CAS Numbers2593402-36-7
Storage Condition0C Short Term, -20C Long Term
SolubilityDMSO
Purity98% by HPLC
SMILES CodeC(C=CCN(C)C)(=O)N1CC=2C(=CC(NC=3N=C(C(C)=CN3)C4=CN(C(C)C)N=C4)=CC2)CC1
ReferencesYang T, et al. N-[Pyrimidin-2-yl]-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms [published online ahead of print, 2020 Nov 30]. J Med Chem. 2020;10.1021acs.jmedchem.0c01488.

More info

JAK2-IN-7, a selective inhibitor targeting Janus Kinase 2 (JAK2), exhibits inhibitory concentrations (IC50) of 3 nM for JAK2, 11.7 nM for SET-2 cells, and 41 nM for BaF3 V617F cells, indicative of its potency and selectivity. This compound demonstrates more than 14-fold selectivity against JAK1, JAK3, and FLT3, underlining its specificity. JAK2-IN-7 effectively induces cell cycle arrest at the G0G1 phase and promotes apoptosis in tumor cells, manifesting significant antitumor activities [1].